Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.01 – $0.02
24% from low
Exchange
OTC Link
CS
Borrow rate
0.29%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.3M | $22.8M | $23.2M | $20.6M | $18.4M | $29.6M | $16.7M | $12.5M |
| Cost of revenue | $827.4K | $1.1M | $2.2M | $3.3M | $2.6M | $1.3M | $1.2M | $857.0K |
| Gross profit | $488.1K | $21.7M | $20.9M | $17.3M | $15.8M | $28.3M | $15.5M | $11.6M |
| Gross margin | 37.1% | 95.2% | 90.3% | 83.9% | 85.9% | 95.5% | 92.8% | 93.1% |
| R&D | $1.4M | $2.2M | $2.4M | $4.1M | $1.7M | $1.2M | $657.0K | $313.0K |
| Operating income | −$10.2M | −$4.5M | −$32.0K | −$6.1M | −$6.6M | $3.5M | −$1.9M | $231.0K |
| EBITDA | −$10.1M | −$27.0M | $7.0M | −$12.8M | −$5.5M | $3.6M | −$910.0K | −$310.0K |
| Net income | −$9.6M | −$54.8M | $1.4M | −$15.9M | −$10.6M | −$3.7M | −$6.5M | −$7.5M |
| Net margin | -729.4% | -241.0% | 5.8% | -77.4% | -57.8% | -12.6% | -38.7% | -60.2% |
| EPS (diluted) | -11.16 | -1.30 | 0.03 | -0.32 | -0.21 | -0.07 | -0.10 | -0.12 |
Annual figures · source: Financial Modeling Prep
EMMAUS LIFE SCIENCES INC
No one on the platform currently holds EMMA.
No tracked institution reports a position in EMMA as of their last filing.
No one on the platform has traded EMMA yet.
| $653980 |
| — |
| ORGSOrgenesis Inc. | $0.40 | +0.00% | $2M | — |
| PHCGPure Harvest Corporate Group, Inc. | $0.02 | -34.52% | $4M | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
Trading at 0.0× sales vs its 0.5× historical median P/S.
Fair value ≈ $0.12 · price $0.01 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
Lowest Volume Rated General Stocks Per 6/15/2026’s Close: 1 – $SRNW 2 – $CIAFF 3 – $ATGFF 4 – $WHTCF 5 – $BLGVF 6 – $VPRB 7 – $MMXLF 8 – $YXT 9 – $NOVTU 10 – $EMMA https://optimizedvalue.xyz/daily-voltech-stock-etf-volume-technical-ratings-6-15-2026/
View on StockTwits ↗Lowest Volume Rated General Stocks Per 9/2/2025’s Close: 1 – $EMMA 2 – $OLNCF 3 – $AVHHL 4 – $LUXH 5 – $NBYCF 6 – $INBP 7 – $SISI 8 – $EMYB 9 – $CULL 10 – $AURX https://optimizedvalue.xyz/daily-voltech-stock-etf-volume-technical-ratings-9-2-2025/
View on StockTwits ↗$EMMA Q1 results show the double-edged sword of cost-cutting: Revenue dipped to $2.4M (-4% YoY) as generics bite, but operating loss narrowed to $1M. Cash reserves now at $1.3M - runway getting tight. The math remains brutal: sickle cell specialization vs generic tsunami and negative equity. Survival mode continues. https://www.prnewswire.com/news-releases/emmaus-life-sciences-reports-quarterly-financial-results-302457162.html
View on StockTwits ↗$EMMA - Emmaus Life Sciences, Inc. - 10K - Updated Risk Factors EMMA faces intensified risks in 2025: widened $9.3M loss, liquidity crunch with debt due and no refinancing, Endari’s U.S. exclusivity expired amid new generic competition and pricing pressure, regulatory setbacks, supply chain issues, and increased dilution and trading volatility risks. #Pharmaceuticals #MarketCompetition #SupplyChain #RegulatoryRisk #FinancialRisk 🟢 Added 🟠 Removed https://d-risk.ai/EMMA/10-K/2025-04-14
View on StockTwits ↗$EMMA's 2024 results paint a grim picture: revenues plummeted 44% due to inventory mismanagement, now sitting on just $1.4M cash. While cost-cutting helped slightly, the $0.10/share loss and negative ops income reveal structural issues. CEO's 2025 optimism feels like rearranging deck chairs on the Titanic - especially with gene therapies looming. https://www.prnewswire.com/news-releases/emmaus-life-sciences-reports-2024-financial-results-302428165.html
View on StockTwits ↗$EMMA new insider buying: 20000 shares. http://insiderbuyingselling.com/?t=EMMA
View on StockTwits ↗$EMMA Emmaus Life Sciences Announces Outcome of FDA Inspection of Postmarketing Adverse Drug Experience Compliance Program
View on StockTwits ↗$QSI - Should I keep QuantumSi and Emmaus Life ( $EMMA ) in the same portfolio? Next fiscal quarter end is on 30th of September 2023 https://www.macroaxis.com/invest/pair-correlation/QSI/EMMA/QuantumSi-vs-Emmaus #portfolio_prospective #better_portfolio #diversify
View on StockTwits ↗Emmaus Life Sciences, Inc. Files SEC Form 8-K $EMMA https://www.marketbeat.com/stocks/OTCMKTS/EMMA/sec-filings/
View on StockTwits ↗$EMMA Emmaus Life Sciences Reports Management Changes https://www.stocktitan.net/news/EMMA/emmaus-life-sciences-reports-management-vslpenln1q18.html
View on StockTwits ↗Emmaus Life Sciences, Inc. Files SEC Form 8-K $EMMA https://www.marketbeat.com/stocks/OTCMKTS/EMMA/sec-filings/
View on StockTwits ↗Emmaus Life Sciences, Inc. Files SEC Form 10-Q $EMMA https://www.marketbeat.com/stocks/OTCMKTS/EMMA/sec-filings/
View on StockTwits ↗$EMMA https://wallstreetwaves.com/emmaus-life-sciences-receives-marketing-authorization-for-endari-in-oman/
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.